325 related articles for article (PubMed ID: 17627454)
21. The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma.
Laport GG
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):59-65. PubMed ID: 16399587
[TBL] [Abstract][Full Text] [Related]
22. Rituximab for follicular lymphoma.
Maloney DG
Curr Hematol Rep; 2003 Jan; 2(1):13-22. PubMed ID: 12901150
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
25. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
Liu Q; Fayad L; Cabanillas F; Hagemeister FB; Ayers GD; Hess M; Romaguera J; Rodriguez MA; Tsimberidou AM; Verstovsek S; Younes A; Pro B; Lee MS; Ayala A; McLaughlin P
J Clin Oncol; 2006 Apr; 24(10):1582-9. PubMed ID: 16575009
[TBL] [Abstract][Full Text] [Related]
26. Recombinant interferon-alpha therapy in patients with follicular lymphoma.
Ozer H; Wiernik PH; Giles F; Tendler C
Cancer; 1998 May; 82(10):1821-30. PubMed ID: 9587113
[TBL] [Abstract][Full Text] [Related]
27. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Montoto S; Moreno C; Domingo-Doménech E; Estany C; Oriol A; Altés A; Besalduch J; Pedro C; Gardella S; Escoda L; Asensio A; Vivancos P; Galán P; de Sevilla AF; Ribera JM; Briones J; Colomer D; Campo E; Montserrat E; López-Guillermo A;
Haematologica; 2008 Feb; 93(2):207-14. PubMed ID: 18223288
[TBL] [Abstract][Full Text] [Related]
28. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
[TBL] [Abstract][Full Text] [Related]
29. Follicular lymphoma, survival, and rituximab: is it time to declare victory?
Horning SJ
J Clin Oncol; 2008 Oct; 26(28):4537-8. PubMed ID: 18662966
[No Abstract] [Full Text] [Related]
30. What is the role of maintenance rituximab in follicular NHL?
Maloney DG
Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
[TBL] [Abstract][Full Text] [Related]
31. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
[TBL] [Abstract][Full Text] [Related]
32. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
33. Ibritumomab: new drug. Interesting concept, disappointing in practice.
Prescrire Int; 2005 Oct; 14(79):171-3. PubMed ID: 16285071
[TBL] [Abstract][Full Text] [Related]
34. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
Weng WK; Levy R
J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
[TBL] [Abstract][Full Text] [Related]
35. Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma.
Ghielmini M
Cancer Treat Rev; 2005 Dec; 31(8):644-7. PubMed ID: 16289339
[No Abstract] [Full Text] [Related]
36. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
37. The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
Lenz G; Hiddemann W; Dreyling M
Cancer; 2004 Sep; 101(5):883-93. PubMed ID: 15329894
[TBL] [Abstract][Full Text] [Related]
38. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
39. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas.
Behl D; Ristow K; Markovic SN; Witzig TE; Habermann TM; Colgan JP; Inwards DJ; White WL; Ansell SM; Micallef IN; Johnston PB; Porrata LF
Br J Haematol; 2007 Jun; 137(5):409-15. PubMed ID: 17433025
[TBL] [Abstract][Full Text] [Related]
40. Management options for follicular lymphoma: observe; R-CHOP; B-R; others?
McLaughlin P
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S91-5. PubMed ID: 22035757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
